Intest Res Search

CLOSE


Search

  • HOME
  • Search
Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis
Fares Ayoub, Matthew Odenwald, Dejan Micic, Sushila R. Dalal, Joel Pekow, Russell D. Cohen, David T. Rubin, Atsushi Sakuraba
Intest Res. 2022;20(2):240-250.   Published online February 8, 2022
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation
Brigida Barberio, Edoardo Vincenzo Savarino, Timothy Card, Cristina Canova, Francesco Baldisser, Alessandro Gubbiotti, Davide Massimi, Matteo Ghisa, Fabiana Zingone
Intest Res. 2022;20(1):114-123.   Published online August 4, 2021
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein
Intest Res. 2022;20(1):72-77.   Published online February 3, 2021
Full text    PubReader    ePub    Crossref - TDM    PDF    
Close layer
prev next
Inflammatory Bowel Diseases
Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study
Rupa Banerjee, Sai Wei Chuah, Ida Normiha Hilmi, Deng-Chyang Wu, Suk-Kyun Yang, Dirk Demuth, Dirk Lindner, Shashi Adsul
Intest Res. 2021;19(1):83-94.   Published online December 31, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
Choon Jin Ooi, Ida Normiha Hilmi, Hyo-Jong Kim, Umesh Jalihal, Deng-Chyang Wu, Dirk Demuth, Dirk Lindner, Shashi Adsul
Intest Res. 2021;19(1):71-82.   Published online September 4, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, Tadashi Yokoyama, Masakazu Nagahori, Tomoki Inaba, Mitsuhiro Shikamura, Takayoshi Yamaguchi, Tetsuharu Hori, Philippe Pinton, Mamoru Watanabe, Toshifumi Hibi
Intest Res. 2021;19(4):448-460.   Published online August 18, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
Hiroyuki Okamoto, Nathanael L. Dirks, Maria Rosario, Tetsuharu Hori, Toshifumi Hibi
Intest Res. 2021;19(1):95-105.   Published online July 10, 2020
Full text    PubReader    ePub    Crossref - TDM    PDF    Supplementary Material
Close layer
prev next
IBD
Current new challenges in the management of ulcerative colitis
Tomohiro Fukuda, Makoto Naganuma, Takanori Kanai
Intest Res. 2019;17(1):36-44.   Published online January 25, 2019
Full text    PubReader    ePub    Crossref - TDM    PDF    
Close layer
prev next
  • SCImago Journal & Country Rank
  • AOCC 2018
  • CSIBD
  • JSIBD
  • kasid
  • TSIBD
  • CCF
  • PubMed Central
  • PubMed
  • KoreaMed
  • KoMCI
  • Scopus
  • Directory of Open Access Journals (DOAJ)
  • GoogleScholar
  • EBSCO
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • ORCID
  • COPE
  • KOFST
  • TrendMD


ABOUT
ARTICLE & TOPICS
Article Category

Browse all articles >

TOPICS

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
Room 310, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145    Fax: +82-2-957-6146    E-mail: thekasid@irjournal.org                

Copyright © 2022 by Korean Association for the Study of Intestinal Diseases.

Developed in M2PI

Close layer
prev next